colorectal cancer
Conditions
Interventions
administration of keishi kajutubu tou (TJ - 18) + Bushi matsu (TJ - 3023)
Sponsors
Wakayama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Histologically confirmed colorectal cancer (2) Patients with adjuvant chemotherapy for stage II and stage III colon cancer with curative resection (3) Patients scheduled to undergo adjuvant chemotherapy including oxaliplatin (4) Patients with age> 20 years (as of the registration date) (5) ECOG PS of 0 or 1 (6) Patients with no major obstructions in major organs (bone marrow, heart, lungs, liver and kidney etc.) (7) Patients with no prior chemotherapy for colorectal cancer (8) Patients provided written informed consent before this study registration
Exclusion criteria
Exclusion criteria: (1) Patients with resistance to taking medicine for traditional Chinese medicine (2) Patients with pre-treatment history of oxaliplatin (3) Patients with duplicated active cancer (4) Patients with severe dysesthesia or dysesthesia with dysfunction (5) Patients with a history of severe drug hypersensitivity (6) Patients with clinically problematic infection (7) Patients in which it was judged that registration in this study was difficult due to clinically problematic mental / neurological diseases (8) Patients with any of the following complications i) diabetes with poor control ii) hypertension with poor control iii) interstitial pneumonia or pulmonary fibrosis iv) intestinal palsy or intestinal obstruction v) clinically problematic heart disease (9) Other patients that the doctor in charge judged unsuitable for safely carrying out this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and efficacy of Keishi Kamisukutou (TJ - 18) + bushi-matsu (TJ - 3023) for oxaliplatin-induced peripheral neuropathy | — |
Countries
Japan
Contacts
Public ContactHiromitsu Iwamoto
Wakayama Medical University Second Department of Surgery
Outcome results
None listed